Table 2.
Response rate for the whole cohort before consolidation in relation to prognostic factors.
| Characteristic | Whole patients, number = 130 (%) | ||||
|---|---|---|---|---|---|
| Response rate before consolidation, number (%) | Total | Univariate | Multivariate | ||
| CR/PR | PD | P-value | P-value | ||
| Regimen | |||||
| ICE | 44 (54.3) | 37 (45.7) | 81 | 0.004 | 0.002 |
| GV | 14 (28.6) | 35 (71.4) | 49 | ||
| Sex | |||||
| Female | 13 (31.7) | 28 (68.3) | 41 | 0.04 | NS |
| Male | 45 (50.6) | 44 (49.4) | 89 | ||
| Age (year) | |||||
| <13 | 44 (53) | 39 (47) | 83 | 0.01 | NS |
| ≥13 | 14 (29.8) | 33 (70.2) | 47 | ||
| Time to relapse | 0.002 | ||||
| Refractory | 3 (10.3) | 26 (89.7) | 29 | 0.0001 | 0.0001 |
| Early relapse | 12 (50) | 12 (50) | 24 | 0.261 | |
| Late relapse (ref) | 43 (55.8) | 34 (44.2) | 77 | ||
| Stage | |||||
| I | 9 (75) | 3 (25) | 12 | 0.01 | NS |
| II | 13 (59.1) | 9 (40.9) | 22 | ||
| III | 16 (50) | 16 (50) | 32 | ||
| IV | 20 (31.3) | 44 (68.7) | 64 | ||
| Bone involvement | |||||
| Absent | 48 (47.5) | 53 (52.5) | 101 | 0.2 | NS |
| Present | 10 (34.5) | 19 (65.5) | 29 | ||
| Bone marrow involvement ~ | |||||
| Absent | 49 (46.7) | 56 (53.3) | 105 | 0.34 | NS |
| Present | 9 (36) | 16 (64) | 25 | ||
| Lung involvement | |||||
| Absent | 51 (51.5) | 48 (48.5) | 99 | 0.005 | NS |
| Present | 7 (22.6) | 24 (77.4) | 31 | ||
| Liver involvement | |||||
| Absent | 55 (49.1) | 57 (50.9) | 112 | 0.01 | NS |
| Present | 3 (16.7) | 15 (83.3) | 18 | ||
| B-symptoms | |||||
| Absent | 30 (68.2) | 14 (31.8) | 44 | 0.001 | 0.002 |
| Present | 13 (31.7) | 28 (68.3) | 41 | ||
| Bulky disease | |||||
| Absent | 52 (46.4) | 60 (53.6) | 112 | 0.3 | NS |
| Present | 6 (33.3) | 12 (66.7) | 18 | ||
| Histology | |||||
| Nodular sclerosis | 31 (41.9) | 43 (58.1) | 74 | 0.8 | NS |
| Others | 18 (43.9) | 23 (56.1) | 41 | ||
| ESR (first hour), mm/h | |||||
| <50 | 31 (66) | 16 (34) | 47 | 0.0001 | NS |
| ≥50 | 21 (30) | 49 (70) | 70 | ||
| WBC, ×10(3)/mcl | |||||
| <13.5 | 49 (51) | 47 (49) | 96 | 0.01 | NS |
| ≥13.5 | 9 (26.5) | 25 (73.5) | 34 | ||
| Hemoglobin, gm/dl | |||||
| <10.5 | 21 (33.9) | 41 (66.1) | 62 | 0.02 | NS |
| ≥10.5 | 37 (54.4) | 31 (45.6) | 68 | ||
| Albumin, gm/dl | |||||
| <3.5 | 14 (48.3) | 15 (51.7) | 29 | 0.7 | NS |
| ≥3.5 | 12 (54.5) | 10 (45.5) | 22 | ||
| LDH, IntUnit/L* | |||||
| <700 | 46 (47.4) | 51 (52.6) | 97 | 0.2 | NS |
| ≥700 | 5 (29.4) | 12 (70.6) | 17 | ||
| Early response | |||||
| CR | 43 (70.5) | 18 (29.5) | 61 | 0.0001 | NS |
| PR | 15 (26.3) | 42 (73.7) | 57 | ||
| PD | 0 (0) | 12 (100) | 12 | ||
ICE, ifosfamide, carboplatin, and etoposide; GV, gemcitabine and vinorelbine; WBC, white blood cell; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; CR, complete response; PR, partial response; PD, progressive disease; NS, not significant.
~Bone marrow involvement by bone marrow biopsy and/or PET/CT. *LDH ≥ 1 × Normal (700 IntUnit/L).